Novo Surges After Hims & Hers Abandons Wegovy Pill Copycat (2)

Feb. 9, 2026, 10:40 AM UTC

Novo Nordisk A/S shares reversed some of last week’s plunge after Hims & Hers Health Inc. pulled a copycat version of the new Wegovy weight-loss pill following US government threats to crack down on knockoffs.

The stock rose as much as 8.6% in Copenhagen trading, clocking its biggest gain so far this year. That follows a decline of more than 20% last week, when the company warned that its sales will fall more than expected this year and Hims & Hers launched its cut-price drug before abruptly reversing course.

WATCH: Novo Nordisk A/S shares rose after Hims & Hers Health Inc. agreed to stop selling a copycat version of the new Wegovy weight-loss pill. Source: Bloomberg

Hims & Hers said it would stop ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.